Engelsk titel: Individualizing biological therapies
Läs online
Författare:
Bergan, Stein
;
Bolstad, Nils
Email: stein.bergan@farmasi.uio.no
Språk: Nor
Antal referenser: 28
Dokumenttyp:
Översikt
UI-nummer: 18030010
Sammanfattning
Background: The number of approved biological drugs is rapidly increasing in different therapeutic areas. Several of the drugs have large inter- and intraindividual variability, which means that there may be a potential for improvement of therapy by personalizing the selection and dosing of these agents.
Material and methods: This review is based on unsystematic literature review and the experience of the authors obtained from a clinical therapeutic drug monitoring (TDM) service.
Results and Conclusion: For biologicals like infliximab and adalimumab, individualization based on concentration measurements and (identifying) titers of anti-drug antibodies (ADA) is already largely established in Norway. For several other biologicals retrospective studies indicate that there may be a potential for optimization through individualized dosing, but evidence in the form of prospective studies is lacking.